Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
J166817-5mg | 5mg | In stock | $29.90 | |
J166817-10mg | 10mg | In stock | $39.90 | |
J166817-25mg | 25mg | In stock | $79.90 | |
J166817-50mg | 50mg | In stock | $139.90 | |
J166817-100mg | 100mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $249.90 | |
J166817-250mg | 250mg | In stock | $499.90 | |
J166817-1g | 1g | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,399.90 |
Potent, selective and cell-permeable BET bromodomain inhibitor
Synonyms | 1268524-70-4|(+)-JQ1|(+)-JQ-1|JQ1 compound|JQ1|(S)-tert-butyl 2-(4-(4-chlorophenyl)-2,3,9-triMethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate|JQ-1|(S)-JQ1|1MRH0IMX0W|CHEMBL1957266|6H-Thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine |
---|---|
Specifications & Purity | 98% (HPLC) |
Storage Temp | Store at -20°C |
Shipped In | Dry ice |
Product Description | Product Describtion: JQ1 is a member of the triazolo-diazepine compound family, which functions as a pan-BET (bromodomain and extra-terminal motif) family inhibitor. JQ1 is known to suppress cell proliferation and therefore, can be used as a therapeutic drug for a number of cancers including multiple myeloma and acute myeloid leukemia. Product Application: (+)-JQ1 has been used in flow cytometry assay, cell viability assay and quantitative PCR assay in order to investigate on the reversal of HIV-1 latency. |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
IUPAC Name | tert-butyl 2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-9-yl]acetate |
---|---|
INCHI | InChI=1S/C23H25ClN4O2S/c1-12-13(2)31-22-19(12)20(15-7-9-16(24)10-8-15)25-17(11-18(29)30-23(4,5)6)21-27-26-14(3)28(21)22/h7-10,17H,11H2,1-6H3/t17-/m0/s1 |
InChi Key | DNVXATUJJDPFDM-KRWDZBQOSA-N |
Canonical SMILES | CC1=C(SC2=C1C(=NC(C3=NN=C(N32)C)CC(=O)OC(C)(C)C)C4=CC=C(C=C4)Cl)C |
Isomeric SMILES | CC1=C(SC2=C1C(=N[C@H](C3=NN=C(N32)C)CC(=O)OC(C)(C)C)C4=CC=C(C=C4)Cl)C |
PubChem CID | 46907787 |
Molecular Weight | 456.99 |
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
L2320232 | Certificate of Analysis | Dec 01, 2023 | J166817 |
L2320233 | Certificate of Analysis | Dec 01, 2023 | J166817 |
L2320235 | Certificate of Analysis | Dec 01, 2023 | J166817 |
J2221359 | Certificate of Analysis | Aug 27, 2022 | J166817 |
J2221360 | Certificate of Analysis | Aug 27, 2022 | J166817 |
J2221361 | Certificate of Analysis | Aug 27, 2022 | J166817 |
J2221362 | Certificate of Analysis | Aug 27, 2022 | J166817 |
J2221363 | Certificate of Analysis | Aug 27, 2022 | J166817 |
E2212082 | Certificate of Analysis | Mar 02, 2022 | J166817 |
E2212114 | Certificate of Analysis | Mar 02, 2022 | J166817 |
E2212116 | Certificate of Analysis | Mar 02, 2022 | J166817 |
E2212117 | Certificate of Analysis | Mar 02, 2022 | J166817 |
E2212121 | Certificate of Analysis | Mar 02, 2022 | J166817 |
E2212125 | Certificate of Analysis | Mar 02, 2022 | J166817 |
E2212126 | Certificate of Analysis | Mar 02, 2022 | J166817 |
Solubility | DMSO: 20 mg/mL, clear |
---|
Starting at $253.90
1. Kim E et al.. (2018) Angelica gigas Nakai and Decursin Downregulate Myc Expression to Promote Cell Death in B-cell Lymphoma.. Sci Rep, 8 (10590). [PMID:30002430] |
2. Yamamoto T et al.. (2020) BRD4 promotes metastatic potential in oral squamous cell carcinoma through the epigenetic regulation of the MMP2 gene.. Br J Cancer, [PMID:32499570] |
3. Matsuda Y et al.. (2022) Downregulation of miR-26 promotes invasion and metastasis via targeting interleukin-22 in cutaneous T-cell lymphoma.. Cancer Sci, 113 (4): (1208-1219). [PMID:35133054] |
4. Albarnaz JD et al.. (2022) Molecular mimicry of NF-κB by vaccinia virus protein enables selective inhibition of antiviral responses.. Nat Microbiol, 7 (154-168). [PMID:34949827] |
5. Kramer M et al.. (2016) Proliferation and Survival of Embryonic Sympathetic Neuroblasts by MYCN and Activated ALK Signaling.. J Neurosci, 36 (40): (10425-10439). [PMID:27707976] |